Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cyclopharm Limited ( (AU:CYC) ) has issued an update.
Cyclopharm Limited addressed an ASX inquiry regarding an increase in the price and volume of its securities, stating that it is not aware of any undisclosed information affecting trading. The company confirmed that it continues to operate within its strategic and commercial plans and complies with ASX listing rules.
More about Cyclopharm Limited
Cyclopharm Limited operates in the healthcare industry, focusing on the development and commercialization of nuclear medicine technologies, including their primary product, Technegas, which is used for lung imaging.
YTD Price Performance: 1.27%
Average Trading Volume: 44,505
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$177.8M
For a thorough assessment of CYC stock, go to TipRanks’ Stock Analysis page.